Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Bronchiolitis Obliterans Syndrome × Photopheresis × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Graft vs Host Disease 1 Bronchiolitis Obliterans Syndrome 1

Interventions

tofacitinib 7 Imatinib Mesylate 5 ibrutinib 3 ofatumumab 2 nilotinib 2 ruxolitinib 1 canakinumab 1 bosutinib 1 Sirolimus 1 Rituximab 1 Proto-Oncogene Proteins c-raf 1 Photopheresis 1 Pentostatin 1 Mycophenolic Acid 1 Methotrexate 1 Infliximab 1 Everolimus 1 Etanercept 1 Dasatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed

330 enrolled 32 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡